Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06908629 · ClinicalTrials.gov registry record · NA
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
A NA study of Cancer and Neuroendocrine Tumors, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06908629: Recruiting NA study of Cancer and Neuroendocrine Tumors, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT06908629 is a NA study of Cancer and Neuroendocrine Tumors that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 120 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06908629, a NA study of Cancer and Neuroendocrine Tumors, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in Metro Detroit, Michigan. Main questions to answer are: * Can we have a completion rate of at least 80% of participants filling out the screening tool? * Can we determine procedures for patient referrals based on social needs * Can we implement brief interventions based on food access and digital inclusion (ensuring everyone has access to the digital technologies they need to participate in society)
Primary Outcome
80% of the 120 participants will complete the American Academy of Family Physicians (AAFP) Social Needs Screening Tool
Conditions Studied
Interventions
- OTHER Implementation of social determinants of health screening and referral
Study Locations (1)
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2027-05 |
| Phase | NA |
What NCT06908629 shows while recruiting
NCT06908629 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Implementation of social determinants of health screening and referral is the first listed.
NCT06908629 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06908629 about?
NCT06908629 is a clinical study titled "Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors". The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in Metro Detroit, Michigan. Main questions to answer are: * Can we have a completion rate of at least 80% of participan...
What is the current status of trial NCT06908629?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-09-03. Estimated completion is 2027-05.
What conditions does trial NCT06908629 study?
This clinical trial studies the following conditions: Cancer, Neuroendocrine Tumors, Cancer Survivors, Gastrointestinal Cancers, Multiple Myeloma, Neoplasms.
What interventions are being tested in trial NCT06908629?
The interventions under investigation include: Implementation of social determinants of health screening and referral (OTHER).
Who is sponsoring clinical trial NCT06908629?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06908629 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06908629's enrollment target sits among peer trials
120 288th of 615 higher than 321 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI